Leerink Partners Downgrades Amgen (AMGN) to Market Perform, 'Awaiting Obesity Results'
Tweet Send to a Friend
(Updated - February 7, 2024 7:11 AM EST)
Leerink Partners analyst David Risinger downgraded Amgen (NASDAQ: AMGN) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Leerink Partners analyst David Risinger downgraded Amgen (NASDAQ: AMGN) from Outperform ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
